Suppr超能文献

左前降支真性分叉病变中边支处理与患者因素的相关性:GRAND-DES 注册研究的分析。

Association of Side-Branch Treatment and Patient Factors in Left Anterior Descending Artery True Bifurcation Lesions: Analysis from the GRAND-DES Pooled Registry.

机构信息

Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital, Seoul 03080, Republic of Korea.

出版信息

J Interv Cardiol. 2020 Dec 27;2020:8858642. doi: 10.1155/2020/8858642. eCollection 2020.

Abstract

METHODS

Patients undergoing PCI to left anterior descending (LAD) bifurcation lesions with contemporary DES were analyzed from a nationwide registry. Baseline risk was assessed using the Age, Creatinine, and Ejection Fraction (ACEF) score. Target lesion failure (TLF), a composite of cardiac death, target vessel myocardial infarction, and target lesion revascularization, was assessed at 3 years.

RESULTS

Among 1,089 patients with LAD bifurcation lesions, 548 (50.3%) patients underwent SB treatment. The SB treatment group showed a nonsignificant, but numerically lower rate of 3-year TLF (6.6% vs. 9.2%, HR 0.75, 95%CI 0.44-1.28,  = 0.29). In patients with low pretreatment risk (ACEF<1.22), SB treatment was associated with a lower rate of 3-year TLF (HR 0.43, 95%CI 0.19-0.96,  = 0.04), while no significant difference was observed in patients with high risk (ACEF≥1.22). The difference in the low risk group was mostly driven by target lesion revascularization (HR 0.24, 95%CI 0.08-0.75,  = 0.01).

CONCLUSIONS

SB treatment for LAD bifurcation lesions showed favorable long-term outcomes compared with main-branch-only intervention, especially in patients with low pretreatment risk.

摘要

方法

本研究分析了一项全国性注册研究中接受经皮冠状动脉介入治疗(PCI)的左前降支(LAD)分叉病变且使用当代 DES 的患者。使用年龄、肌酐和射血分数(ACEF)评分评估基线风险。在 3 年时评估终点事件(TLF),包括心源性死亡、靶血管心肌梗死和靶病变血运重建的复合终点。

结果

在 1089 例 LAD 分叉病变患者中,548 例(50.3%)患者接受了边支(SB)治疗。SB 治疗组 3 年 TLF 的发生率虽较低,但无统计学差异(6.6% vs. 9.2%,HR 0.75,95%CI 0.44-1.28, = 0.29)。在低预处理风险(ACEF<1.22)患者中,SB 治疗与较低的 3 年 TLF 发生率相关(HR 0.43,95%CI 0.19-0.96, = 0.04),而在高风险患者(ACEF≥1.22)中未观察到显著差异。低风险组的差异主要归因于靶病变血运重建(HR 0.24,95%CI 0.08-0.75, = 0.01)。

结论

与仅主支干预相比,SB 治疗 LAD 分叉病变显示出良好的长期结局,尤其是在低预处理风险患者中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ab4/7781708/3731990e4922/JITC2020-8858642.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验